| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 in Human Breast Cancer Is Mediated by Selective Promoter Usage
Department of Molecular and Biomedical Pharmacology, University of Kentucky College of Medicine, Lexington, Kentucky
Peroxisome proliferator-activated receptor-
1 (PPAR
1) is transactivated by a wide range of ligands in normal human mammary epithelial and breast cancer cells. Although transactivation of PPAR
mediates the expression of genes that are markers of differentiation, its overexpression in cancers of the breast, thyroid, colon, and lung suggests its dysregulation may play a role in oncogenesis, cancer progression, or both. We report the overexpression of PPAR
is caused by the use of a tumor-specific promoter in breast cancer cells that is distinct from the promoter used in normal epithelia. Thus, the increase in PPAR
expression seen in breast cancer cells results from promoter recruitment, providing new insights into the expression and actions of PPAR
in breast cancer.
This article has been cited by other articles:
![]() |
C. N. Johnstone, P. S. Mongroo, A. S. Rich, M. Schupp, M. J. Bowser, A. S. deLemos, J. W. Tobias, Y. Liu, G. E. Hannigan, and A. K. Rustgi Parvin- Inhibits Breast Cancer Tumorigenicity and Promotes CDK9-Mediated Peroxisome Proliferator-Activated Receptor Gamma 1 Phosphorylation Mol. Cell. Biol., January 15, 2008; 28(2): 687 - 704. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wirtenberger, S. Tchatchou, K. Hemminki, J. Schmutzhard, C. Sutter, R. K. Schmutzler, A. Meindl, B. Wappenschmidt, M. Kiechle, N. Arnold, et al. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer Carcinogenesis, November 1, 2006; 27(11): 2201 - 2208. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Suzuki, S Hayashi, Y Miki, Y Nakamura, T Moriya, A Sugawara, T Ishida, N Ohuchi, and H Sasano Peroxisome proliferator-activated receptor {gamma} in human breast carcinoma: a modulator of estrogenic actions. Endocr. Relat. Cancer, March 1, 2006; 13(1): 233 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Konopleva, W. Zhang, Y.-X. Shi, T. McQueen, T. Tsao, M. Abdelrahim, M. F. Munsell, M. Johansen, D. Yu, T. Madden, et al. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol. Cancer Ther., February 1, 2006; 5(2): 317 - 328. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |